Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884256 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
A Phase 2 study, sponsored by Cloudbreak Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT04884256: Completed Phase 2 study, sponsored by Cloudbreak Therapeutics.
NCT04884256 is a Phase 2 study that has completed, run by Cloudbreak Therapeutics. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04884256, a Phase 2 study, has completed, sponsored by Cloudbreak Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.
Interventions
- DRUG CBT-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
What the finished NCT04884256 record still lists
NCT04884256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 1 intervention - of which CBT-004 is the first listed.
NCT04884256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04884256 about?
NCT04884256 is a clinical study titled "Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula". STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators,...
What is the current status of trial NCT04884256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2023-12-21. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT04884256?
The interventions under investigation include: CBT-004 (DRUG).
Who is sponsoring clinical trial NCT04884256?
This trial is sponsored by Cloudbreak Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04884256's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI